Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 oct. 2025 16h00 HE | Source: Zymeworks Inc.

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and...
13 oct. 2025 12h00 HE | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative,...
13 oct. 2025 08h05 HE | Source: Auron Therapeutics Inc.

Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit

Auron Therapeutics will participate in the 8th Annual Targeted Protein Degradation (TPD) & Induced Proximity Summit in Boston.
13 oct. 2025 07h30 HE | Source: Bicara Therapeutics Inc.

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...
13 oct. 2025 07h00 HE | Source: Lifecore Biomedical, Inc.

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
10 oct. 2025 16h01 HE | Source: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for...
10 oct. 2025 08h00 HE | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD program, CTX460, is the first investigational candidate to...
10 oct. 2025 07h00 HE | Source: Inspire Medical Systems

Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings

MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative,...
09 oct. 2025 07h30 HE | Source: Pyxis Oncology

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today...
08 oct. 2025 21h52 HE | Source: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for...

Page précédente

Page suivante